Drugs / DPV-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04470024 | Aug 2021 → Dec 2027 expected | head and neck cancer | Providence Health & Services | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2020-10-18 | UbiVac | Results Dr Bernard Fox Joins CCFDIE Immunotherapy Workshop to Talk UbiVac's Combination Immunotherapy for Advanced Breast Cancer ubivac.com ↗
He showed results from UbiVac’s phase I/II study of vaccination as adjuvant treatment for definitively treated non-small cell lung cancer (NSCLC) where vaccination with UbiVac’s DPV-001 induced immune responses to a wide spectrum of shared cancer antigens. |
| 2018-06-11 | UbiVac | Results UbiVac Releases New Lung Cancer Research Data: DPV-001 Vaccine Can Improve Treatment Response Rates ubivac.com ↗
DPV-001, a 100-plus antigen, vaccine-based immunotherapy has induced or boosted broad anti-cancer responses in all patients studied to date. |
| 2018-06-11 | UbiVac | Results Portland’s UbiVac To Detail Progress With New Cancer Therapy at International Immuno-Oncology Forum in New York ubivac.com ↗
This week Dr. Fox will outline positive results documenting induction of immunity against a wide spectrum of cancer targets in patients with non-small cell lung cancer (NSCLC). |
| 2018-06-07 | UbiVac | Results Positive Immune Response Data for Patients Receiving DPV-001 Presented by UbiVac at Society for Immunotherapy of Cancer Meeting ubivac.com ↗
Dr. Christopher Paustian, a scientist at UbiVac, is presenting preliminary results documenting the ability of UbiVac’s DRibble® cancer vaccine, DPV-001, to induce CD4 and CD8 T cell immunity. |
| 2018-06-07 | UbiVac | Results Portland’s UbiVac To Detail Progress With New Cancer Therapy at International Immuno-Oncology Forum in Chicago ubivac.com ↗
Dr. Fox will outline positive early results documenting induction of immunity against a wide spectrum of cancer targets in patients with non-small cell lung cancer (NSCLC). |
| 2018-06-07 | UbiVac | Results Portland’s UbiVac To Brief International Immuno-Oncology Forum in Chicago ubivac.com ↗
Dr. Fox will outline positive early results documenting induction of immunity against a wide spectrum of cancer targets in patients with non-small cell lung cancer (NSCLC). |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DPV-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04470024 ↗ |
| Modality | Vaccine | “autophagosome cancer vaccine” NCT04470024 ↗ |